Cerulean Pharma

Cerulean Pharma Inc. (NASDAQ: CERU) is not the most active stock, and it has a mere $123 million market cap, but it has a substantial upside call for its cancer targets of nanoparticle-drug conjugates that target tumors. Cerulean was started as Overweight at Barclays on Tuesday, with a price target of $8.00. This has a $4.51 price now after falling 9% on Friday. While Barclays is not a call to double, Cerulean was started as Buy at Roth in late August with a $9.00 price target and Canaccord Genuity’s price target from August was $15.00.

Cerulean could double and still not even hit its 52-week high, as that range in the past year has been $2.77 to $10.87. Investors also need to understand that Cerulean has no revenues to speak of, but it did end the June quarter with some $85 million in cash and net tangible assets of $68 million.

Spectranetics

Spectranetics Corp. (NASDAQ: SPNC) is honestly very hard to think of as a double after the price action we have seen. Still, two firms see massive upside. The company’s products are used to treat arterial blockages in the legs and heart, as well as for removing pacemaker and defibrillator cardiac leads. All the news on it is class action suits after shares have been pounded. After the sell-off we saw that Benchmark started Spectranetics with a Buy rating and a $24.00 price target. Shares were at $14.80 before the call, and closed at $12.52. Piper Jaffray kept an Outperform rating and a $25 price target. Still, others don’t believe in it. UBS started it as Sell with a $12.00 price target last week too in a “beware of falling daggers” call.

Spectranetics’ 52-week range keeps getting lower and is currently $12.40 to $37.04. Again, this one has been pounded, and perhaps that 52-week range speaks for itself. The company used to be worth over $1 billion, but the market cap is now $532 million. Spectranetics also is expected by the analysts who follow it to keep seeing revenue growth ahead, but it is expected to keep posting a loss in earnings per share for at least this year and next.

Turtle Beach

Turtle Beach Corp. (NASDAQ: HEAR) could have 200% upside here if Oppenheimer’s call from this last week comes true. Oppenheimer started coverage with a report called “Coming In Loud and Clear,” with Turtle Beach as the best in class headset for gaming. It started Turtle Beach with an Outperform rating and a $6.00 price target, with its target being late in 2016.

Turtle Beach’s prior close was $2.03, and shares closed at $2.14 on Friday, with a 52-week range of $1.75 to $7.65. This one is also very small, with a $90 million market cap, and we covered it with much more detail during the week.

ALSO READ: 8 Great Value Stocks Trading Under 10 Times Earnings

24/7 Wall St. again wants to remind readers that they need to do an incredible amount of their own research before deciding on the validity of highly speculative stocks. Analysts from Wall Street often have perceived conflicts of interest because they have an investment banking relationship or they seek to have one. Many analysts also have no additional information or insight than an institutional investor. If investors want even more harsh disclosures, this has been covered in prior aggressive calls and a more detailed risk warning can be read.